Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model

Vaccine

Volumn 27, Issue 39, 2009, Pages 5383-5392

  Tsai, Yuh Shyan ^a,b   Shiau, Ai Li ^a   Chen, Yu Fon ^a   Tsai, Hsin Tzu ^b   Lee, Hwei Ling ^a   Tzai, Tzong Shin ^b   Wu, Chao Liang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Electrogene transfer; HER2; Interleukin 12

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA INTERFERON; HER2 SCFV ANTIBODY IL 12 FUSION PROTEIN; HYBRID PROTEIN; INTERLEUKIN 12; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; GENE TRANSFER; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SPLEEN; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68349092709     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.079     Document Type: Article

References (47)

1. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Cancer 2 2 (2001) 127-137
2. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357 1 (2007) 39-51
3. Gandour-Edwards R., Lara Jr. P.N., Folkins A.K., LaSalle J.M., Beckett L., Li Y., et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer 95 5 (2002) 1009-1015
4. Tsai Y.S., Tzai T.S., and Chow N.H. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?. Urol Int 79 3 (2007) 210-216
5. Jimenez R.E., Hussain M., Bianco Jr. F.J., Vaishampayan U., Tabazcka P., Sakr W.A., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7 8 (2001) 2440-2447
6. Kruger S., Weitsch G., Buttner H., Matthiensen A., Bohmer T., Marquardt T., et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 102 5 (2002) 514-518
7. Kruger S., Weitsch G., Buttner H., Matthiensen A., Bohmer T., Marquardt T., et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21 5 (2002) 981-987
8. Latif Z., Watters A.D., Dunn I., Grigor K.M., Underwood M.A., and Bartlett J.M. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89 7 (2003) 1305-1309
9. Latif Z., Watters A.D., Dunn I., Grigor K., Underwood M.A., and Bartlett J.M. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?. Eur J Cancer 40 1 (2004) 56-63
10. Caner V., Turk N.S., Duzcan F., Tufan N.L., Kelten E.C., Zencir S., et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 14 3 (2008) 261-266
11. Magnifico A., Albano L., Campaner S., Campiglio M., Pilotti S., Menard S., et al. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res 67 11 (2007) 5308-5317
12. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 5 (2005) 341-354
13. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13 16 (2007) 4677-4685
14. Nastala C.L., Edington H.D., McKinney T.G., Tahara H., Nalesnik M.A., Brunda M.J., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153 4 (1994) 1697-1706
15. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178 4 (1993) 1223-1230
16. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., and Kruit W.H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52 3 (2003) 133-144
17. Cohen J. IL-12 deaths: explanation and a puzzle. Science 270 5238 (1995) 908
18. Janat-Amsbury M.M., Yockman J.W., Lee M., Kern S., Furgeson D.Y., Bikram M., et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 9 6 (2004) 829-836
19. Hill H.C., Conway Jr. T.F., Sabel M.S., Jong Y.S., Mathiowitz E., Bankert R.B., et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62 24 (2002) 7254-7263
20. Halin C., Rondini S., Nilsson F., Berndt A., Kosmehl H., Zardi L., et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20 3 (2002) 264-269
21. Peng L.S., Penichet M.L., and Morrison S.L. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 163 1 (1999) 250-258
22. Heuser C., Diehl V., Abken H., and Hombach A. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. Int J cancer 106 4 (2003) 545-552
23. De Lorenzo C., Palmer D.B., Piccoli R., Ritter M.A., and D'Alessio G. A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8 6 (2002) 1710-1719
24. Neve R.M., Nielsen U.B., Kirpotin D.B., Poul M.A., Marks J.D., and Benz C.C. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun 280 1 (2001) 274-279
25. Suzuki M., Shinkai M., Honda H., Kamihira M., Iijima S., and Kobayashi T. Construction of tumor-specific cells expressing a membrane-anchored single-chain Fv of anti-ErbB-2 antibody. Biochim Biophys Acta 1525 1-2 (2001) 191-196
26. De Lorenzo C., Tedesco A., Terrazzano G., Cozzolino R., Laccetti P., Piccoli R., et al. A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91 6 (2004) 1200-1204
27. Tsai YS, Shiau AL, Chen YF, Tsai HT, Tzai TS, Wu CL. Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene via genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy. Cancer Gene Ther (2009), doi:10.1038/cgt.2009.41.
28. Mickey D.D., Mickey G.H., Murphy W.M., Niell H.B., and Soloway M.S. In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors. J Urol 127 6 (1982) 1233-1237
29. Shieh G.S., Shiau A.L., Yo Y.T., Lin P.R., Chang C.C., Tzai T.S., et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 66 20 (2006) 9957-9966
30. Shiau A.L., Lin Y.P., Shieh G.S., Su C.H., Wu W.L., Tsai Y.S., et al. Development of a conditionally replicating pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy. Mol Ther 15 1 (2007) 131-138
31. Lode H.N., Dreier T., Xiang R., Varki N.M., Kang A.S., and Reisfeld R.A. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 95 5 (1998) 2475-2480
32. de Graaf M., van der Meulen-Muileman I.H., Pinedo H.M., and Haisma H.J. Expression of scFvs and scFv fusion proteins in eukaryotic cells. Methods Mol Biol 178 (2002) 379-387
33. De Lorenzo C., Arciello A., Cozzolino R., Palmer D.B., Laccetti P., Piccoli R., et al. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64 14 (2004) 4870-4874
34. Heo D.S., Park J.G., Hata K., Day R., Herberman R.B., and Whiteside T.L. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 50 12 (1990) 3681-3690
35. Helguera G., Dela Cruz J.S., Lowe C., Ng P.P., Trinh R., Morrison S.L., et al. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine 24 3 (2006) 304-316
36. Garratt A.N., Ozcelik C., and Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med 13 2 (2003) 80-86
37. Negro A., Brar B.K., and Lee K.F. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59 (2004) 1-12
38. Lode H.N., Xiang R., Dreier T., Varki N.M., Gillies S.D., and Reisfeld R.A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91 5 (1998) 1706-1715
39. Li S., Zhang X., and Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 94 10 (2002) 762-768
40. Waldo G.S., Standish B.M., Berendzen J., and Terwilliger T.C. Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol 17 7 (1999) 691-695
41. Arafat W.O., Gomez-Navarro J., Buchsbaum D.J., Xiang J., Wang M., Casado E., et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther 9 4 (2002) 256-262
42. Lieschke G.J., Rao P.K., Gately M.K., and Mulligan R.C. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 15 1 (1997) 35-40
43. Kriegsmann J., Berndt A., Hansen T., Borsi L., Zardi L., Brauer R., et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Int 24 1 (2004) 25-33
44. Parihar R., Nadella P., Lewis A., Jensen R., De Hoff C., Dierksheide J.E., et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients. Clin Cancer Res 10 15 (2004) 5027-5037
45. Killion J.J., Radinsky R., and Fidler I.J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17 3 (1998-1999) 279-284
46. Smyth M.J., Taniguchi M., and Street S.E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165 5 (2000) 2665-2670
47. Wonderlich J., Shearer G., Livingstone A., and Brooks A. Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol (2006) 3.11.1-3.11.23